Skip to main content
Premium Trial:

Request an Annual Quote

Roche Nabs CE Mark for Three Cobas Respiratory Test Panels

NEW YORK – Roche said on Wednesday that three of its molecular respiratory panels have received CE marking and have been launched in countries accepting the CE mark.

The PCR-based tests simultaneously detect and differentiate between common respiratory pathogens. One test is for influenza A/B and respiratory syncytial virus; one is for adenovirus, human metapneumovirus, and enterovirus/rhinovirus; and the third is for parainfluenza 1, 2, 3, and 4.

Running on the Cobas Omni Utility Channel for use with Cobas 6800/8800 systems, the tests can be performed together or individually from a single nasopharyngeal swab sample, the company said in a statement.

"Our latest set of syndromic respiratory solutions allows clinicians to choose the appropriate tests based on the healthcare setting, season, and patient needs," Thomas Schinecker, CEO of Roche Diagnostics, said in a statement. "By testing only what is medically relevant and necessary, we enable targeted therapy, avoid misuse of antibiotics, and reduce unnecessary intervention."

The Basel, Switzerland-based company added that it is "looking to expand availability of these tests beyond CE markets in the future."

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.